{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:22:34Z","timestamp":1785493354349,"version":"3.56.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Minimal residual disease (MRD) is a critical prognostic marker in acute lymphoblastic leukemia (ALL). The well studied and used MRD detection methods, multiparametric flow cytometry (MFC) and real-time quantitative polymerase chain reaction (qRT-PCR) for fusion genes and receptor gene rearrangements have significantly improved risk stratification, but have limitations in sensitivity and applicability. Next-generation sequencing (NGS) has emerged as a promising approach for MRD assessment, offering better sensitivity and the ability to track clonal evolution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This systematic review evaluates the clinical utility and prognostic value of NGS for MRD detection in ALL, comparing its performance with conventional methods and exploring its potential role in therapeutic guidance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive literature search was conducted across PubMed and Web of Science following PRISMA guidelines. Studies were included if they assessed MRD using NGS in ALL patients and provided data on sensitivity and prognostic value. Comparative analyses with MFC or qRT-PCR were considered. Data on end-of-induction MRD values, event-free survival (EFS), and overall survival (OS) were extracted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen studies met the inclusion criteria. NGS demonstrated superior sensitivity in detecting MRD-positive cases compared to MFC in patients classified as MRD-negative. Higher correlation was observed in MRD-positive cases than in MRD-negative cases. NGS-based MRD stratification correlated strongly with clinical outcomes, with patients achieving NGS-MRD negativity exhibiting superior EFS and OS rates. Additionally, NGS was highly predictive of relapse following hematopoietic stem cell transplantation and CAR-T cell therapy. The IGH rearrangements as the primary marker in NGS panels has demonstrated good prognostic value in B-ALL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>NGS represents a transformative tool for MRD monitoring in ALL, offering enhanced sensitivity and prognostic accuracy. Challenges such as high costs, complex bioinformatics analysis and the need for standardization remain. While its integration into clinical practice holds significant promise, further research is needed to establish standardized protocols, cost-effectiveness, and its optimal role in treatment decision-making. The combination of NGS with MFC may provide complementary advantages.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1570041","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:27:52Z","timestamp":1745299672000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The emerging role of next-generation sequencing in minimal residual disease assessment in acute lymphoblastic leukemia: a systematic review of current literature"],"prefix":"10.3389","volume":"12","author":[{"given":"Andreea-Iulia","family":"\u0218tefan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leti\u021bia-Elena","family":"Radu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Jardan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Coli\u021b\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"ref1","year":"2025"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Cancer J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3345\/kjp.2017.60.5.129","article-title":"Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean","volume":"60","author":"Lee","year":"2017","journal-title":"J Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41375-021-01448-2","article-title":"Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study","volume":"36","author":"Moorman","year":"2021","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1056\/NEJM199808273390904","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"339","author":"Cav\u00e9","year":"1998","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy","volume":"31","author":"Pui","year":"2017","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40291-017-0277-9","article-title":"Is next-generation sequencing the way to go for residual disease monitoring in acute lymphoblastic leukemia?","volume":"21","author":"Kotrova","year":"2017","journal-title":"Mol Diagn Therapy"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4149\/neo_2014_017","article-title":"Monitoring of minimal residual disease in acute leukemia by multiparametric flow cytometry","volume":"61","author":"Kusenda","year":"2013","journal-title":"Neoplasma"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2013","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","article-title":"Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS","volume":"33","author":"Scheijen","year":"2019","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-13-3231","article-title":"Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH","volume":"20","author":"Wu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/bjh.14420","article-title":"Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia","volume":"176","author":"Sekiya","year":"2017","journal-title":"Br J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cca.2018.10.037","article-title":"Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia","volume":"488","author":"Jo","year":"2019","journal-title":"Clin Chim Acta"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1182\/blood-2021-150350","article-title":"Igh-V(D)J NGS-MRD measurement in pediatric B-acute lymphoblastic leukemia","volume":"138","author":"Lu","year":"2021","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1182\/blood-2021-152369","article-title":"Performance of next generation sequencing for minimal residual disease detection for pediatric patients with acute lymphoblastic leukemia: results from the prospective clinical trial DFCI 16-001","volume":"138","author":"Paolino","year":"2021","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"957743","DOI":"10.3389\/fonc.2022.957743","article-title":"Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia","volume":"12","author":"Lee","year":"2022","journal-title":"Front Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after Tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Discovery"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1007\/s00432-022-04151-6","article-title":"Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"149","author":"Mai","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"7468","DOI":"10.1038\/s41467-023-43171-9","article-title":"Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1182\/blood-2023-190624","article-title":"Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL)","volume":"142","author":"Roy","year":"2023","journal-title":"Crit Rev Oncog"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3343\/alm.2023.0412","article-title":"Comparison of measurable residual disease in pediatric B-lymphoblastic leukemia using multiparametric flow cytometry and next-generation sequencing","volume":"44","author":"Hwang","year":"2024","journal-title":"Ann Lab Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1182\/blood-2012-05-429811","article-title":"Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia","volume":"120","author":"Gawad","year":"2012","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.jmoldx.2021.06.005","article-title":"Next-generation sequencing-based Clonality assessment of Ig gene rearrangements: a multicenter validation study by EuroClonality-NGS","volume":"23","author":"Van den Brand","year":"2021","journal-title":"J Mol Diag"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1182\/blood-2024-198602","article-title":"Integrating next generation flow cytometry and next-generation sequencing for an enhanced detection of measurable residual disease in acute myeloid leukemia with myelodysplasia-related gene mutations","volume":"144","author":"Pi\u00f1ero","year":"2024","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1182\/blood-2023-187041","article-title":"Using next generation sequencing of flow cytometry CD markers and machine learning as a replacement to flow cytometry analysis for the diagnosis of hematologic neoplasms","volume":"142","author":"Albitar","year":"2023","journal-title":"Blood"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1570041\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:27:52Z","timestamp":1745299672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1570041\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":30,"alternative-id":["10.3389\/fmed.2025.1570041"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1570041","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"article-number":"1570041"}}